| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Tract Infections | 60 | 2023 | 321 | 14.370 |
Why?
|
| Bacteriuria | 34 | 2022 | 77 | 13.130 |
Why?
|
| Catheter-Related Infections | 29 | 2020 | 270 | 7.850 |
Why?
|
| Antimicrobial Stewardship | 15 | 2022 | 84 | 5.920 |
Why?
|
| Anti-Bacterial Agents | 53 | 2023 | 2992 | 5.630 |
Why?
|
| Urinary Catheterization | 24 | 2019 | 117 | 5.410 |
Why?
|
| Urinary Catheters | 13 | 2018 | 31 | 3.870 |
Why?
|
| Spinal Cord Injuries | 12 | 2023 | 374 | 3.650 |
Why?
|
| Cystitis | 7 | 2023 | 107 | 3.590 |
Why?
|
| Inappropriate Prescribing | 6 | 2019 | 50 | 2.790 |
Why?
|
| Urinalysis | 10 | 2022 | 84 | 2.400 |
Why?
|
| Catheters, Indwelling | 15 | 2020 | 374 | 2.400 |
Why?
|
| Asymptomatic Infections | 9 | 2019 | 34 | 2.380 |
Why?
|
| Cross Infection | 11 | 2020 | 544 | 2.120 |
Why?
|
| Anti-Infective Agents | 7 | 2023 | 446 | 1.960 |
Why?
|
| Escherichia coli | 17 | 2024 | 1203 | 1.920 |
Why?
|
| Nursing Homes | 10 | 2021 | 99 | 1.770 |
Why?
|
| Hospitals, Veterans | 7 | 2019 | 397 | 1.730 |
Why?
|
| Fluoroquinolones | 7 | 2024 | 126 | 1.670 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2020 | 1209 | 1.610 |
Why?
|
| Antibiosis | 5 | 2017 | 15 | 1.560 |
Why?
|
| Bacteremia | 7 | 2018 | 689 | 1.510 |
Why?
|
| Veterans | 11 | 2023 | 1641 | 1.440 |
Why?
|
| Escherichia coli Infections | 8 | 2023 | 241 | 1.440 |
Why?
|
| Urine | 9 | 2021 | 143 | 1.430 |
Why?
|
| Enterobacteriaceae | 3 | 2018 | 46 | 1.390 |
Why?
|
| Bacterial Adhesion | 5 | 2012 | 147 | 1.380 |
Why?
|
| Drug Utilization | 4 | 2020 | 179 | 1.340 |
Why?
|
| Biofilms | 6 | 2012 | 199 | 1.290 |
Why?
|
| Unnecessary Procedures | 4 | 2019 | 104 | 1.270 |
Why?
|
| Nonprescription Drugs | 2 | 2019 | 52 | 1.240 |
Why?
|
| Gram-Negative Bacterial Infections | 4 | 2022 | 158 | 1.190 |
Why?
|
| Catheters | 5 | 2023 | 126 | 1.170 |
Why?
|
| Infection Control | 9 | 2023 | 270 | 1.170 |
Why?
|
| Phage Therapy | 4 | 2023 | 23 | 1.150 |
Why?
|
| Bacteriophages | 6 | 2023 | 71 | 1.110 |
Why?
|
| Humans | 148 | 2024 | 261506 | 1.100 |
Why?
|
| Attitude of Health Personnel | 5 | 2020 | 918 | 1.090 |
Why?
|
| Prostatitis | 2 | 2023 | 18 | 1.070 |
Why?
|
| Medical Audit | 3 | 2018 | 188 | 1.040 |
Why?
|
| Catheterization, Peripheral | 3 | 2020 | 158 | 0.900 |
Why?
|
| Natural Language Processing | 4 | 2016 | 119 | 0.900 |
Why?
|
| Diagnostic Errors | 4 | 2016 | 509 | 0.890 |
Why?
|
| Physicians | 4 | 2023 | 882 | 0.880 |
Why?
|
| Internship and Residency | 4 | 2022 | 1375 | 0.860 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2023 | 418 | 0.860 |
Why?
|
| Pyelonephritis | 1 | 2022 | 39 | 0.830 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 1303 | 0.830 |
Why?
|
| Pyuria | 1 | 2021 | 6 | 0.810 |
Why?
|
| Health Personnel | 3 | 2017 | 625 | 0.790 |
Why?
|
| United States | 26 | 2023 | 15433 | 0.790 |
Why?
|
| Electronic Health Records | 5 | 2016 | 929 | 0.780 |
Why?
|
| Prosthesis-Related Infections | 2 | 2021 | 232 | 0.770 |
Why?
|
| Enterococcus faecalis | 3 | 2011 | 49 | 0.720 |
Why?
|
| Self Medication | 1 | 2019 | 23 | 0.710 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2019 | 13 | 0.700 |
Why?
|
| Drug Resistance, Microbial | 3 | 2021 | 218 | 0.680 |
Why?
|
| Medicine | 1 | 2021 | 137 | 0.680 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2018 | 69 | 0.670 |
Why?
|
| Inpatients | 4 | 2018 | 678 | 0.660 |
Why?
|
| Guideline Adherence | 5 | 2017 | 636 | 0.660 |
Why?
|
| Nitrofurantoin | 2 | 2023 | 8 | 0.650 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 1085 | 0.640 |
Why?
|
| Hospitalization | 5 | 2019 | 2083 | 0.610 |
Why?
|
| Disease Notification | 1 | 2017 | 11 | 0.610 |
Why?
|
| Female | 58 | 2024 | 141928 | 0.610 |
Why?
|
| Osteomyelitis | 2 | 2019 | 236 | 0.600 |
Why?
|
| Treatment Failure | 3 | 2019 | 1391 | 0.600 |
Why?
|
| Epidemiological Monitoring | 1 | 2017 | 73 | 0.590 |
Why?
|
| Hospitals | 7 | 2023 | 485 | 0.580 |
Why?
|
| Hospitalists | 1 | 2018 | 57 | 0.580 |
Why?
|
| General Surgery | 1 | 2020 | 326 | 0.580 |
Why?
|
| Enterococcus | 3 | 2019 | 59 | 0.570 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2018 | 605 | 0.570 |
Why?
|
| Length of Stay | 3 | 2018 | 1900 | 0.570 |
Why?
|
| Physicians, Women | 1 | 2018 | 105 | 0.570 |
Why?
|
| Long-Term Care | 5 | 2021 | 83 | 0.560 |
Why?
|
| Formative Feedback | 1 | 2016 | 33 | 0.560 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 573 | 0.560 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 5 | 2024 | 72 | 0.550 |
Why?
|
| Medical Overuse | 1 | 2016 | 45 | 0.550 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 203 | 0.550 |
Why?
|
| Lactobacillus | 2 | 2014 | 58 | 0.550 |
Why?
|
| Male | 51 | 2024 | 123000 | 0.540 |
Why?
|
| Oncologists | 1 | 2018 | 134 | 0.540 |
Why?
|
| Patients | 1 | 2018 | 245 | 0.530 |
Why?
|
| Documentation | 2 | 2016 | 207 | 0.520 |
Why?
|
| Biodiversity | 1 | 2015 | 91 | 0.510 |
Why?
|
| Ciprofloxacin | 4 | 2024 | 89 | 0.510 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2017 | 233 | 0.510 |
Why?
|
| Bacterial Infections | 3 | 2023 | 479 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 2403 | 0.500 |
Why?
|
| Extraintestinal Pathogenic Escherichia coli | 3 | 2021 | 17 | 0.500 |
Why?
|
| Prevalence | 10 | 2022 | 3260 | 0.500 |
Why?
|
| Attitude to Health | 1 | 2018 | 465 | 0.500 |
Why?
|
| Algorithms | 3 | 2017 | 3890 | 0.490 |
Why?
|
| Clinical Competence | 5 | 2014 | 1270 | 0.490 |
Why?
|
| Mass Screening | 2 | 2019 | 1509 | 0.480 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 135 | 0.480 |
Why?
|
| Aged | 31 | 2023 | 70117 | 0.470 |
Why?
|
| Adult | 36 | 2023 | 77950 | 0.470 |
Why?
|
| Surveys and Questionnaires | 11 | 2023 | 5687 | 0.470 |
Why?
|
| Chronic Disease | 2 | 2023 | 1819 | 0.470 |
Why?
|
| Middle Aged | 34 | 2024 | 86204 | 0.460 |
Why?
|
| Urinary Bladder | 2 | 2022 | 575 | 0.460 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 1054 | 0.450 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 36 | 0.440 |
Why?
|
| Pseudomonas Phages | 1 | 2012 | 10 | 0.440 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2020 | 252 | 0.430 |
Why?
|
| Fimbriae, Bacterial | 2 | 2011 | 66 | 0.430 |
Why?
|
| Feedback | 3 | 2021 | 198 | 0.430 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2011 | 7 | 0.420 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 1171 | 0.420 |
Why?
|
| Diabetic Foot | 3 | 2020 | 154 | 0.420 |
Why?
|
| Models, Theoretical | 1 | 2016 | 785 | 0.410 |
Why?
|
| Retrospective Studies | 19 | 2023 | 37905 | 0.410 |
Why?
|
| Thrombelastography | 3 | 2021 | 79 | 0.400 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2024 | 994 | 0.400 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2022 | 202 | 0.400 |
Why?
|
| Health Services Research | 2 | 2020 | 233 | 0.400 |
Why?
|
| Nitrofurazone | 1 | 2010 | 2 | 0.390 |
Why?
|
| Nanostructures | 1 | 2011 | 94 | 0.390 |
Why?
|
| Primary Health Care | 5 | 2024 | 787 | 0.390 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 254 | 0.390 |
Why?
|
| Silver | 1 | 2010 | 34 | 0.380 |
Why?
|
| Rhodobacteraceae | 1 | 2010 | 2 | 0.380 |
Why?
|
| Endocarditis | 1 | 2012 | 125 | 0.380 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 29902 | 0.380 |
Why?
|
| Prospective Studies | 12 | 2021 | 12873 | 0.380 |
Why?
|
| Urology | 1 | 2011 | 128 | 0.370 |
Why?
|
| Microbiota | 2 | 2021 | 547 | 0.360 |
Why?
|
| Uropathogenic Escherichia coli | 2 | 2022 | 24 | 0.360 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 295 | 0.360 |
Why?
|
| Medication Errors | 1 | 2011 | 174 | 0.350 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2009 | 60 | 0.350 |
Why?
|
| Microbial Viability | 3 | 2021 | 62 | 0.350 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 799 | 0.350 |
Why?
|
| Outpatients | 5 | 2023 | 462 | 0.340 |
Why?
|
| Clostridium Infections | 1 | 2013 | 252 | 0.340 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 748 | 0.340 |
Why?
|
| Blood | 4 | 2021 | 156 | 0.340 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 128 | 0.340 |
Why?
|
| Efficiency | 2 | 2020 | 99 | 0.340 |
Why?
|
| Abdomen | 2 | 2021 | 332 | 0.340 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 173 | 0.310 |
Why?
|
| Heart Failure | 1 | 2021 | 2516 | 0.310 |
Why?
|
| Risk Factors | 10 | 2024 | 17523 | 0.310 |
Why?
|
| Biomedical Research | 1 | 2015 | 806 | 0.300 |
Why?
|
| Proteus | 1 | 2006 | 1 | 0.300 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2013 | 317 | 0.300 |
Why?
|
| Proteus Infections | 1 | 2006 | 3 | 0.300 |
Why?
|
| Urinary Calculi | 1 | 2006 | 25 | 0.300 |
Why?
|
| Paresis | 1 | 2007 | 54 | 0.290 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2007 | 104 | 0.290 |
Why?
|
| Bacteriological Techniques | 3 | 2019 | 121 | 0.290 |
Why?
|
| Central Venous Catheters | 2 | 2020 | 98 | 0.290 |
Why?
|
| Skin Tests | 1 | 2007 | 96 | 0.280 |
Why?
|
| Internal Medicine | 3 | 2017 | 124 | 0.280 |
Why?
|
| Staphylococcus aureus | 4 | 2021 | 548 | 0.280 |
Why?
|
| Aortic Valve | 1 | 2010 | 581 | 0.280 |
Why?
|
| Catheterization | 2 | 2008 | 410 | 0.270 |
Why?
|
| Colicins | 1 | 2005 | 4 | 0.270 |
Why?
|
| Escherichia coli K12 | 1 | 2005 | 4 | 0.270 |
Why?
|
| Fever | 2 | 2021 | 497 | 0.270 |
Why?
|
| Chlorhexidine | 2 | 2004 | 88 | 0.260 |
Why?
|
| Functional Laterality | 1 | 2007 | 316 | 0.260 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2004 | 121 | 0.260 |
Why?
|
| Patient Discharge | 2 | 2021 | 661 | 0.250 |
Why?
|
| Gammaproteobacteria | 1 | 2024 | 19 | 0.240 |
Why?
|
| Risk Assessment | 5 | 2018 | 6869 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 15694 | 0.230 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.230 |
Why?
|
| Prescriptions | 1 | 2023 | 65 | 0.230 |
Why?
|
| Spinal Cord Diseases | 1 | 2023 | 90 | 0.220 |
Why?
|
| 2-Propanol | 1 | 2002 | 10 | 0.220 |
Why?
|
| Antisepsis | 1 | 2002 | 12 | 0.220 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 622 | 0.210 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 860 | 0.210 |
Why?
|
| Surgeons | 2 | 2020 | 519 | 0.210 |
Why?
|
| Cohort Studies | 4 | 2018 | 9244 | 0.210 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 4314 | 0.210 |
Why?
|
| Iodine | 1 | 2002 | 54 | 0.210 |
Why?
|
| Blood Specimen Collection | 1 | 2002 | 93 | 0.200 |
Why?
|
| Return to Work | 1 | 2021 | 17 | 0.200 |
Why?
|
| Texas | 7 | 2020 | 6311 | 0.200 |
Why?
|
| Gram-Negative Bacteria | 1 | 2022 | 100 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2023 | 250 | 0.200 |
Why?
|
| Viral Tail Proteins | 1 | 2021 | 7 | 0.200 |
Why?
|
| Bacteria | 4 | 2023 | 611 | 0.200 |
Why?
|
| Microbial Interactions | 1 | 2021 | 17 | 0.200 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2015 | 490 | 0.190 |
Why?
|
| Critical Illness | 3 | 2021 | 714 | 0.190 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2021 | 54 | 0.190 |
Why?
|
| Language | 1 | 2023 | 309 | 0.190 |
Why?
|
| Postoperative Period | 2 | 2021 | 665 | 0.190 |
Why?
|
| Communicable Diseases | 1 | 2023 | 193 | 0.190 |
Why?
|
| Career Choice | 1 | 2022 | 232 | 0.180 |
Why?
|
| Thrombophilia | 1 | 2020 | 56 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 4744 | 0.180 |
Why?
|
| Polysaccharides | 1 | 2021 | 197 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2002 | 362 | 0.180 |
Why?
|
| Female Urogenital Diseases | 1 | 2019 | 12 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 140 | 0.170 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 383 | 0.170 |
Why?
|
| Male Urogenital Diseases | 1 | 2019 | 18 | 0.170 |
Why?
|
| Recurrence | 3 | 2019 | 4758 | 0.170 |
Why?
|
| Residence Characteristics | 1 | 2022 | 348 | 0.170 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 6009 | 0.170 |
Why?
|
| Quality Improvement | 2 | 2016 | 851 | 0.170 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 635 | 0.170 |
Why?
|
| Data Mining | 2 | 2016 | 88 | 0.170 |
Why?
|
| Relative Value Scales | 1 | 2018 | 14 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 402 | 0.160 |
Why?
|
| Employee Performance Appraisal | 1 | 2018 | 21 | 0.160 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2018 | 45 | 0.160 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 164 | 0.160 |
Why?
|
| Coliphages | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sepsis | 1 | 2004 | 652 | 0.160 |
Why?
|
| Bacteriolysis | 1 | 2018 | 11 | 0.160 |
Why?
|
| Diagnosis-Related Groups | 1 | 2018 | 25 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 552 | 0.160 |
Why?
|
| Urination Disorders | 1 | 2018 | 61 | 0.160 |
Why?
|
| Safety Management | 1 | 2019 | 132 | 0.160 |
Why?
|
| Stroke | 1 | 2007 | 1144 | 0.160 |
Why?
|
| Siderophores | 1 | 2017 | 11 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 324 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 181 | 0.160 |
Why?
|
| Aortic Rupture | 1 | 2019 | 113 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2013 | 492 | 0.160 |
Why?
|
| Recovery of Function | 1 | 2021 | 703 | 0.150 |
Why?
|
| Homes for the Aged | 1 | 2017 | 24 | 0.150 |
Why?
|
| Audiovisual Aids | 1 | 2017 | 42 | 0.150 |
Why?
|
| DNA, Bacterial | 2 | 2010 | 558 | 0.150 |
Why?
|
| Metals | 1 | 2018 | 155 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 294 | 0.150 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2016 | 11 | 0.150 |
Why?
|
| Gastric Mucosa | 1 | 2021 | 613 | 0.150 |
Why?
|
| Acetylcysteine | 2 | 2008 | 143 | 0.140 |
Why?
|
| Americas | 1 | 2016 | 52 | 0.140 |
Why?
|
| Skin | 1 | 2002 | 1259 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2021 | 295 | 0.140 |
Why?
|
| Patient Participation | 1 | 2020 | 446 | 0.140 |
Why?
|
| Colony Count, Microbial | 2 | 2009 | 149 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 430 | 0.140 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 1148 | 0.140 |
Why?
|
| Research | 1 | 2019 | 415 | 0.140 |
Why?
|
| Health Literacy | 1 | 2017 | 118 | 0.140 |
Why?
|
| Minocycline | 2 | 2008 | 182 | 0.140 |
Why?
|
| Goals | 1 | 2017 | 185 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 915 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2017 | 329 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2018 | 289 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2019 | 619 | 0.130 |
Why?
|
| Leg | 1 | 2016 | 226 | 0.130 |
Why?
|
| Veterans Health | 1 | 2017 | 181 | 0.130 |
Why?
|
| Propensity Score | 1 | 2018 | 750 | 0.130 |
Why?
|
| Utilization Review | 1 | 2015 | 48 | 0.130 |
Why?
|
| Motivation | 1 | 2018 | 499 | 0.130 |
Why?
|
| Professional Competence | 1 | 2016 | 136 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 275 | 0.130 |
Why?
|
| Mannose | 2 | 2011 | 40 | 0.130 |
Why?
|
| Data Collection | 3 | 2013 | 620 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 1085 | 0.130 |
Why?
|
| Program Development | 1 | 2016 | 261 | 0.130 |
Why?
|
| Time Factors | 4 | 2020 | 12926 | 0.130 |
Why?
|
| Corynebacterium | 1 | 2014 | 13 | 0.130 |
Why?
|
| Surface Properties | 2 | 2011 | 180 | 0.120 |
Why?
|
| Acute Disease | 2 | 2017 | 2422 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 860 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2018 | 498 | 0.120 |
Why?
|
| Social Norms | 1 | 2014 | 8 | 0.120 |
Why?
|
| Caregivers | 1 | 2020 | 677 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2019 | 2218 | 0.120 |
Why?
|
| Staphylococcus | 1 | 2014 | 86 | 0.120 |
Why?
|
| Pregnancy | 5 | 2024 | 7573 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 671 | 0.120 |
Why?
|
| Reference Standards | 1 | 2015 | 339 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 289 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2019 | 795 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2019 | 674 | 0.120 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2013 | 8 | 0.120 |
Why?
|
| Qualitative Research | 3 | 2020 | 556 | 0.120 |
Why?
|
| Biopsy | 2 | 2019 | 3443 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 1323 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 764 | 0.110 |
Why?
|
| Candida | 1 | 2014 | 164 | 0.110 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 267 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2017 | 621 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2013 | 161 | 0.110 |
Why?
|
| Educational Status | 1 | 2014 | 397 | 0.110 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2011 | 6 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2014 | 298 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2022 | 2588 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 899 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2016 | 6100 | 0.100 |
Why?
|
| Telemedicine | 1 | 2017 | 471 | 0.100 |
Why?
|
| Adolescent | 4 | 2019 | 31252 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 335 | 0.100 |
Why?
|
| Device Removal | 1 | 2013 | 337 | 0.100 |
Why?
|
| Fibrinolysis | 2 | 2021 | 63 | 0.100 |
Why?
|
| Alkynes | 1 | 2010 | 29 | 0.100 |
Why?
|
| Silicon | 1 | 2010 | 48 | 0.100 |
Why?
|
| Phenazines | 1 | 2010 | 13 | 0.100 |
Why?
|
| Gentian Violet | 1 | 2010 | 20 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2021 | 2803 | 0.100 |
Why?
|
| Comorbidity | 1 | 2017 | 2352 | 0.090 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 103 | 0.090 |
Why?
|
| HIV Infections | 2 | 2013 | 2134 | 0.090 |
Why?
|
| Vancomycin | 1 | 2012 | 273 | 0.090 |
Why?
|
| Neutropenia | 3 | 2019 | 968 | 0.090 |
Why?
|
| Education, Medical | 1 | 2014 | 331 | 0.090 |
Why?
|
| Communication | 3 | 2023 | 876 | 0.090 |
Why?
|
| Anticoagulants | 3 | 2021 | 787 | 0.090 |
Why?
|
| Polyamines | 1 | 2009 | 75 | 0.090 |
Why?
|
| Patient Safety | 1 | 2015 | 649 | 0.090 |
Why?
|
| Microscopy | 1 | 2010 | 182 | 0.080 |
Why?
|
| Operon | 1 | 2008 | 53 | 0.080 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 257 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2013 | 667 | 0.080 |
Why?
|
| Silicones | 1 | 2008 | 54 | 0.080 |
Why?
|
| Quality of Life | 2 | 2021 | 4532 | 0.080 |
Why?
|
| Phylogeny | 1 | 2010 | 826 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2022 | 32848 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1053 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 419 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 21445 | 0.070 |
Why?
|
| Hypertension | 1 | 2016 | 1503 | 0.070 |
Why?
|
| Equipment Contamination | 1 | 2007 | 90 | 0.070 |
Why?
|
| Plasmids | 1 | 2008 | 837 | 0.070 |
Why?
|
| Transplant Recipients | 2 | 2019 | 324 | 0.070 |
Why?
|
| Leadership | 2 | 2020 | 254 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 615 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2021 | 548 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2020 | 5542 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 419 | 0.060 |
Why?
|
| Trauma Severity Indices | 1 | 2004 | 98 | 0.060 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2004 | 159 | 0.060 |
Why?
|
| Silver Sulfadiazine | 1 | 2004 | 15 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2007 | 621 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 2314 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 255 | 0.060 |
Why?
|
| Vaccines, Inactivated | 1 | 2004 | 175 | 0.060 |
Why?
|
| Providencia | 1 | 2003 | 3 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 383 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2004 | 270 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2024 | 204 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 1183 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 6089 | 0.060 |
Why?
|
| Pharmacists | 1 | 2023 | 95 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 2483 | 0.050 |
Why?
|
| Age Factors | 2 | 2019 | 5377 | 0.050 |
Why?
|
| Child | 4 | 2019 | 29154 | 0.050 |
Why?
|
| Intention | 2 | 2013 | 109 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 210 | 0.050 |
Why?
|
| Catheterization, Central Venous | 2 | 2020 | 354 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2021 | 39 | 0.050 |
Why?
|
| Adaptation, Biological | 1 | 2021 | 49 | 0.050 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 25 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2021 | 93 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2008 | 945 | 0.050 |
Why?
|
| beta-Lactamases | 1 | 2023 | 179 | 0.050 |
Why?
|
| Drug Antagonism | 1 | 2020 | 32 | 0.050 |
Why?
|
| Candidiasis | 1 | 2003 | 262 | 0.050 |
Why?
|
| Symbiosis | 1 | 2021 | 77 | 0.050 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 223 | 0.050 |
Why?
|
| Reflex | 1 | 2020 | 68 | 0.050 |
Why?
|
| Catholicism | 1 | 2020 | 9 | 0.050 |
Why?
|
| Hospitals, Religious | 1 | 2020 | 7 | 0.050 |
Why?
|
| Coronavirus | 1 | 2020 | 40 | 0.050 |
Why?
|
| Virulence Factors | 1 | 2021 | 213 | 0.040 |
Why?
|
| Mice | 4 | 2022 | 34495 | 0.040 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 124 | 0.040 |
Why?
|
| Quadriplegia | 1 | 2019 | 43 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 259 | 0.040 |
Why?
|
| Models, Organizational | 1 | 2019 | 76 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 1618 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1021 | 0.040 |
Why?
|
| Paraplegia | 1 | 2019 | 95 | 0.040 |
Why?
|
| Syndrome | 1 | 2002 | 1351 | 0.040 |
Why?
|
| Organoids | 1 | 2021 | 287 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 37 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 543 | 0.040 |
Why?
|
| Vaccination | 1 | 2004 | 1123 | 0.040 |
Why?
|
| Animals | 5 | 2022 | 59536 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 46 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 598 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 497 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 1320 | 0.040 |
Why?
|
| Biosynthetic Pathways | 1 | 2017 | 46 | 0.040 |
Why?
|
| Colorectal Surgery | 1 | 2017 | 32 | 0.040 |
Why?
|
| Colostomy | 1 | 2017 | 70 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2017 | 171 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2021 | 739 | 0.040 |
Why?
|
| Bacterial Translocation | 1 | 2017 | 26 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 500 | 0.040 |
Why?
|
| Marfan Syndrome | 1 | 2019 | 142 | 0.040 |
Why?
|
| Nursing Staff | 1 | 2016 | 15 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 1313 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 1555 | 0.040 |
Why?
|
| Practice Management, Medical | 1 | 2016 | 22 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2017 | 75 | 0.040 |
Why?
|
| Virulence | 1 | 2017 | 323 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 256 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2017 | 155 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 313 | 0.030 |
Why?
|
| Utah | 1 | 2015 | 43 | 0.030 |
Why?
|
| Wound Healing | 1 | 2021 | 815 | 0.030 |
Why?
|
| Vocabulary, Controlled | 1 | 2015 | 24 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 288 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2017 | 286 | 0.030 |
Why?
|
| Cryoelectron Microscopy | 1 | 2017 | 243 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 717 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 3472 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 181 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2017 | 359 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 1546 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7222 | 0.030 |
Why?
|
| Iron | 1 | 2017 | 376 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 672 | 0.030 |
Why?
|
| Thrombosis | 1 | 2020 | 781 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 1274 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 672 | 0.030 |
Why?
|
| Machine Learning | 1 | 2015 | 319 | 0.030 |
Why?
|
| Pneumonia | 1 | 2019 | 751 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2017 | 1732 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 698 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 291 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 356 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 4971 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2010 | 29 | 0.020 |
Why?
|
| Alkylation | 1 | 2010 | 29 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Infant | 1 | 2006 | 13310 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 4917 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2010 | 75 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2006 | 16273 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 350 | 0.020 |
Why?
|
| Dendrimers | 1 | 2009 | 8 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2884 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 392 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 515 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8223 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 756 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1582 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 208 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 5673 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1141 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2008 | 157 | 0.020 |
Why?
|
| Epithelium, Corneal | 1 | 2009 | 223 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 792 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 671 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2007 | 61 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 2594 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 14889 | 0.010 |
Why?
|
| Cell Survival | 1 | 2009 | 3045 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 1818 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 5114 | 0.010 |
Why?
|